Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3856_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Contributors
- •Introduction
- •New Problems
- •Acute Ischemic Stroke Paradigm Shift
- •Robotics
- •New Procedures
- •New Practitioners
- •New Impactful Skill Sets
- •The Transradial Wave
- •Conclusions
- •References
- •2: Minimally Invasive Intracerebral Hemorrhage Removal
- •Introduction
- •STICH Trial
- •Craniopuncture
- •Endoport-Mediated Evacuation
- •Endoscope-Assisted Evacuation
- •Adjunctive Aspiration Devices
- •Surgiscope
- •Other Techniques
- •Conclusions
- •References
- •References
- •Augmented Reality
- •Postoperative Monitoring
- •Patient Outcomes
- •Conclusion
- •References
- •Introduction
- •Embolic Protection Devices
- •The Evidence Against Distal Embolic Protection
- •Conclusions
- •References
- •Introduction
- •Specialized Neurologic Emergency Departments
- •Conclusion
- •References
- •Introduction
- •Increased CSF Production
- •Increased Intracranial Blood Volume
- •Diagnosis
- •Management
- •Conservative
- •Surgical Treatment
- •Optic Nerve Sheath Fenestration (ONSF)
- •Cerebrospinal Fluid Diversion
- •Venous Sinus Stenting
- •Background
- •Outcomes
- •Prestenting Evaluation
- •Technique
- •Summary
- •References
- •8: Robotic-Assisted Endovascular Intervention
- •Introduction
- •History
- •Robotic-Assisted Endovascular Work
- •CorPath GRX System
- •Telerobotic Intervention
- •Limitations
- •Conclusions
- •References
- •Introduction
- •Familial Aneurysms
- •Autosomal Dominant Polycystic Kidney Disease
- •Conclusions
- •References
- •Introduction
- •Large Ischemic Core
- •Tandem Occlusions
- •Intra-arterial Neuroprotection
- •References
- •Index

212
O. Doron et al.
Flowgate2 BGC). The ASTER trial documented a trend toward
better mTICI 3 and better clinical outcomes in BGC-treated
patients, using direct aspiration.
Aside from aspiration, stent retrievers, and a combination of
the two, additional methods include distal-protection devices and
rescue stenting. The “Lazarus effect cover-assisted MT” is a distal
embolization protection device for stent retriever thrombectomy.
It features a funnel-shaped nitinol mesh designed to surround the
stent retriever and the enmeshed thrombus during retrieval.
Following stent retriever deployment, the Lazarus device is
positioned at its proximal end, and the retraction of the stent
retriever against the device results in it inverting and rolling over
the outside of the stent retriever. This protective sheath presumably prevents clot fragmentation and distal embolization and has
also been used with distal aspiration techniques.
Another method is “rescue stenting.” While it is uncommonly
used due to reperfusion rates in AIS LVO being in the 90% range,
it is practical for a subset of patients in whom recanalization fails.
One of the key reasons for failure of EVT is underlying intracranial atherosclerotic stenosis (ICAS). ICAS is routinely diagnosed
during the EVT procedure by repeated recanalization and then
acute reocclusion of the vessel. In a Korean series of failed EVTs,
this occurred in up to 77% of the patients. Presently, no guidelines
exist for the optimum treatment in patients who failed
thrombectomy. An alternate technique is to perform permanent
stenting in an attempt to preserve the patency of the vessel.
The effectiveness of “rescue stenting” was demonstrated in an
initial study of 45 failed thrombectomy patients, where the 17
patients with rescue stenting had better outcomes and less cerebral herniation than the 28 non-stenting patient [61]. This technique was validated in a large retrospective analysis of patients
from 16 Korean stroke centers. In this study, patients with anterior
circulation LVOs who failed to recanalize following EVT were
split into rescue stenting and non-rescue stenting groups. Out of
the 148 failed EVT patients, 48 received rescue stenting and 100
did not. Subsequent results show that 31 out of 48 rescue stenting
patients (64.6%) had successful mTICI 2b-3 reperfusion with rescue stenting, while none of the 100 patients without rescue stent-

10 Endovascular Management and Treatment of Acute Ischemic…
213
ing achieved reperfusion. Good functional outcome at 3months
was observed in 39.6% of the rescue stenting group and in 22.0%
of the non-rescue stenting group (p=0.031) without an increase
in SICH or mortality. Moreover, in the rescue stenting group with
successful reperfusion, 54.8% achieved good outcome despite the
initial EVT failure, equivalent to the functional outcomes with
mTICI 2b-3 reperfusion in the initial EVT attempts of 55.4%.
A meta-analysis on rescue stenting, which included articles
from 2015 to 2019, supported these results. In a sample of 352
patients, there was improved outcomes in the stenting arm compared with the refractory occlusion arm (OR, 2.87; 95% CI,
1.77–4.66; p< 0.001; I2, 0%) with reduced mortality, but there
was some heterogeneity between studies for mortality (OR, 0.39;
95% CI, 0.16–0.93; p=0.03; I2, 43%).
In a recent multinational study on emergency rescue stenting in
AIS involving seven neurovascular centers, good outcome was
observed in 73 out of 163 (44.8%) patients with recorded outcomes at 90 days. This is considerably better than the rates of
7–22% found in cohorts with reocclusion or persistent occlusion
reports without rescue stenting. However, the rate of SICH in this
analysis (11%) was higher than in the aggregated thrombectomy
studies without intracranial stenting of 4.4%, and this was more
common in anterior circulation occlusions than posterior circulation occlusions. A lower number of thrombectomy attempts
before rescue stenting were correlated with better functional outcomes.
The decision to perform rescue stenting is complex, as the permanent placement of a stent requires either acute glycoprotein
2b/3a inhibitors or dual antiplatelet treatment to prevent acute
reocclusion due to in-stent thrombosis. In acute stroke patients
with already sizable amounts of ischemic or infarcted tissue, these
medications contribute to a potentially higher risk of symptomatic
intracranial hemorrhage. Presently, there is limited data and a lack
of consensus regarding antiplatelet management for intracranial
stenting during thrombectomy.
As can be concluded from the heterogeneous nature of LVO
AIS, there are still concerns unanswered by the guidelines. These
imminent questions describe subsets of patients who are still fre-

214
O. Doron et al.
quently encountered and for whom future studies would elucidate
the best treatment algorithm.
Large Ischemic Core
While the present guidelines clearly indicate that EVT should be
performed for patients without a large early infarct or with an
ASPECTS of six or more, there exists a substantial proportion of
patients who present to the hospital with an AIS with a sizable
ischemic core. While the evidence is unclear, these patients may
still derive some benet from EVT.Pending the outcomes of randomized controlled trials, core-lab adjudicated pooled analyses of
existing studies may shed preliminary insight into this crucial
question.
In a study pooling data from seven randomized trials with a
total of 1764 patients, of which 871 were in the EVT arm and
893in the best medical treatment arm, it was indicated that EVT
was associated with better functional outcomes across a wide
range of pretreatment imaging types on ordinal shift analyses
[64]. This included all ASPECTS groups, except for ASPECTS
0–2, in which the low sample size was not statistically signicant.
However, this should be interpreted with caution, as in patients
with a large ischemic burden or ASPECTS 4 or less, EVT was
associated with signicantly more SICH.
Similarly, a secondary analysis of the Optimizing Patient
Selection for Endovascular Treatment in Acute Ischemic Stroke
(SELECT) trial demonstrated that EVT was associated with better functional independence (mRS 0–2) compared with medical
management alone (OR, 3.27; 95% CI, 1.11–9.62; p = 0.03).
Moreover, EVT was also associated with less infarct growth and
smaller nal infarct volume than medical treatment [66]. These
aforementioned analyses provide a strong evidence to support further investigation of the use of EVT for patients with large infarcts
and poor ASPECTS at baseline.
The preliminary results from these studies led to the ongoing
SELECT-2 trial, which was designed to evaluate thrombectomy
compared with medical management in distal ICA and MCA M1

10 Endovascular Management and Treatment of Acute Ischemic…
215
occlusions with a large core on either CT (ASPECTS 3–5) or
advanced perfusion imaging (rCBF <30% or ADC<620 or 50ml
or more). The tentative completion date of this trial is at the end of
2021 [67]. Other ongoing clinical trials, such as TENSION
(NCT03094715), TESLA (NCT03805308), and IN EXTREMIS
[68, 69], are also actively recruiting patients and will provide conclusive evidence on the use of EVT in patients with a large ischemic core at presentation [67].
Clinically Mild Strokes withLVO
Another subset of patients are those who present with LVOs but
mild strokes clinically. These scenarios are typically dened at
NIHSS threshold of <5, where the risk of the EVT procedure
needs to be weighed carefully against the potential benet. A
pooled data analysis was conducted featuring six comprehensive
stroke centers with 300 patients having LVO and NIHSS 0–5,
with 80 patients undergoing EVT and 220 patients undergoing
best medical therapy [70]. The best medical treatment group
allowed for rescue EVT if there was subsequent neurological
deterioration. While the groups were not similar, EVT was associated with better functional outcomes (OR, 3.1; 95% CI, 1.4–6.9),
and in a propensity-matched analysis, the superiority of EVT over
best medical treatment persisted (84.4% vs. 70.1%; P = 0.03)
[64].
Recently, another meta-analysis pooled patient data from 16
centers from 2013 to 2017. This study evaluated 251 patients with
LVO and mild stroke, of which 138 were treated with EVT and
113 with best medical treatment. The results demonstrated that
the 3-month functional outcomes were better in the best medical
treatment group when compared with the EVT group (77.4% vs.
88.5%; p= 0.02) [37]. The rate of asymptomatic ICH was also
lower in the best medical management group as compared with
the EVT group (4.6% vs. 17.5%; p=0.002). Moreover, there was
no difference in the rate of reperfusion or in safety outcomes
between the two groups [64, 66, 71].

216
O. Doron et al.
It is expected that future RCTs will further elucidate if mild
strokes with LVO should be treated via EVT.One of these RCTs
is ENDOLOW, which is studying anterior circulation occlusions
with NIHSS scores 0–5 and is enrolling patients in Canada, the
USA, Germany, and Sweden. The INEXTREMIS trial also features a sub-study that is evaluating ischemic stroke patients with
an NIHSS<6 and LVO occlusions and aims to answer this important question [71].
Very Late Presenting Patients: Acute Stroke
Beyond 24Hours
Recent evidence from the AURORA study, which pooled data
from six randomized trials to examine effect of EVT in anterior
circulation proximal LVO stroke from 6 to 24h from time last
seen well, suggests a potential benet of EVT in achieving
reduced disability on functional outcome in terms of mRS in this
group of patients, with an adjusted common odds ratio of 2.54
(95% CI, 1.82–3.54; p<0.0001). Moreover, the number needed
to treat to reduce mRS by 1 point was three patients. Furthermore,
no signicant differences in mortality or SICH were seen between
EVT and control groups [72]. This further validates the results of
previous trials, which supported the fact that carefully selected
patients benet from thrombectomy up to 24hours [61, 73].
However, there is another subset of patients who present after
24hours. Presently, no clinical trials or guidelines detailing how
we can manage these patients exist. Kim etal. studied the benet
of EVT in patients presenting very late [74]. In a subgroup analysis of 150 patients, who presented more than 16h from their last
known well time, EVT was performed only in 24 patients, but a
propensity-matched analysis showed it was associated with
increased odds of having favorable functional recovery at
3months (adjusted OR, 11.08; 95% CI, 1.88–108.60). In a further
subgroup of patients 24 hours from last known well, EVT was
associated with favorable outcomes as well (adjusted OR, 10.54;
95% CI, 2.18–59.34) [75]. These preliminary studies provide evi-

10 Endovascular Management and Treatment of Acute Ischemic…
217
dence in support of a possibility of maintaining the penumbra
beyond 24hours in patients with good collaterals [74].
Direct toThrombectomy Table: No IV tPA
Timing directly impacts the functional outcome in acute stroke
thrombectomy, as any delay in treatment initiation negatively
impacts patients’ functional outcomes [67, 76]. While IV-tPA can
recanalize acute stroke occlusions, EVT has shown higher rate of
recanalization. Hence, there is now a school of thought that
instead of administering IV tPA, whether at an intervening primary stroke center or the comprehensive stroke center, patients
with AIS from an LVO should be treated with EVT.
The SKIP trial, a RCT carried out in Japan, enrolled 200 AIS
patients with anterior circulation occlusions presenting within
4hours of onset [68]. At 3months, the rate of good functional
outcome was similar between the direct thrombectomy (59%) and
combined bridging approach (57%). Moreover, both groups were
found to have a similar mortality rate. However, this trial was
unable to prove noninferiority of direct to thrombectomy over
bridging IV tPA (0.6mg/kg Japanese standardized dose), attributable to it being underpowered with a modest sample size. While
the rate of asymptomatic hemorrhage and SICH did not
signicantly differ between both arms, the combined rate of any
ICH was signicantly lower for the EVT group.
Two other trials, similar in design to the SKIP trial were conducted in China, across multiple stroke centers, also studied
bridging IV tPA in thrombectomy. The DIRECT-MT trial, with
656 enrolled patients, revealed that endovascular thrombectomy
alone was noninferior to combined intravenous alteplase and
endovascular thrombectomy when considering the functional outcome at 90days (adjusted common odds ratio, 1.07; 95% condence interval, 0.81–1.40; p=0.04 for noninferiority). In addition,
the noninferiority margin was set at a high value of 20% margin
of condence in this trial. The noninferiority test in the DEVT
trial also highlighted that the endovascular thrombectomy alone
was noninferior to the combined IV thrombolysis and endovascu-

218
O. Doron et al.
lar thrombectomy group (z=2.7157, p for noninferiority=0.003)
[69, 70]. This trial was terminated after the rst interim analysis
in May 2020 due to the outcome measured having surpassed the
prespecied efcacy boundary. In this study, there was no signicantly different rate of symptomatic ICH between groups; however, the rate of any ICH is signicantly higher in the bridging
r-TPA and thrombectomy group. It is worth noting that given
these trials were performed in East Asian populations, further evidence is needed in a more diverse population. The SWIFTDIRECT, MR CLEAN NOIV, and DIRECT-SAFE trials are
upcoming international RCTs that can fulll this role as they aim
to provide more information on the adoption of thrombectomy
alone approach against bridging IV tPA [70].
Tandem Occlusions
A tandem occlusion (TO) is a thromboembolic obstruction in the
intracranial cerebral vasculature in combination with an extracranial carotid artery occlusion. It can occur in up to one-sixth of
ischemic stroke patients [37]. Typically, TOs do not have good
recanalization rates with IV tPA, and therefore EVT is suggested
[22]. In fact, subgroup analyses of the ESCAPE and MR CLEAN
studies indicated that patients with TO have better outcomes with
early or concurrent treatment of the extracranial occlusion rather
than later in a staged procedure [77, 78]. Nonetheless, there is a
lack of consensus on the optimal endovascular procedure for
acute TO.
The present issue pertains to the best method of treating TO in
acute stroke. The point of contention is if it is better to initially
bypass the extracranial occlusion and remove the intracranial
occlusion rst before returning to tackle the extracranial stenosis
(the “retrograde” approach) or if it is preferable to attempt primary recanalization of the extracranial occlusion rst before moving on to treat the intracranial occlusion (the “antegrade”
approach). The antegrade approach uses primary stenting to jail
the extracranial stenotic atheromatous plaque, thereby preventing

10 Endovascular Management and Treatment of Acute Ischemic…
219
distal emboli [78]. One potential drawback of the antegrade
approach is the procedural time used for carotid stent placement,
as it creates a delay in the time to intracranial reperfusion, possibly resulting in an increase of the nal infarct volume [75, 79].
Furthermore, stent retriever-based thrombectomy techniques have
the potential of entanglement between the struts of the stent
retriever and carotid stent during withdrawal if the guiding catheter cannot be advanced through the carotid stent. Moreover, the
retrograde approach achieves intracranial recanalization faster,
and some purport that this gives better functional outcomes [75];
however, it may be difcult to pass through the proximal occlusion, and subsequent emboli from the proximal occlusion can
sometimes reocclude the intracranial circulation.
Type ofAnesthesia forThrombectomy
For patients treated with EVT particularly, anesthesia has indicated benets, especially when considering complex anatomy,
difcult cases, or restless and aphasic patients. The type of anesthesia used may impact the success outcomes for mechanical
thrombectomy. General anesthesia (GA) may improve procedural
safety preventing body movement as well as protecting the airway, while conscious sedation (CS) allows for neurologic monitoring with hemodynamic stability and a quicker puncture time
[80]. Due to the lack of a consensus in the present literature, a
preference for which type of anesthesia to use is undetermined.
Initial retrospective studies often based their anesthesia choice
on patient characteristics and the comfort level of the administrator. A retrospective study featuring 1174 patients from 2009 to
2013 concluded that GA was inferior to CS; however, there was
limited data on the important factors such as blood pressure and
the NIHSS.Furthermore, their outcomes studied were only mortality and length of stay [80]. Conversely, another retrospective
database study of 2512 patients concluded the opposite: that CS
was superior to GA for stroke interventions [81].

220
O. Doron et al.
Intra-arterial Neuroprotection, Middle Vessel
Occlusion, andAI-Powered Tools inAIS: New
Frontiers
A deeper understanding of the use of EVT for AIS treatment presents an opportunity to address multiple prevention and treatment
aspects, attributable to the various technological innovations combined with extensive data on patients and interventions, and
unprecedented computing processing. In this chapter, we focus
specically on potential innovative directions in endovascular
invasive therapies which could drive future AIS treatment.
Stroke Secondary toDistal Medium-Vessel
Occlusion
Distal medium-vessel occlusion (DMVO) recanalization presents further challenges to vessel recanalization, despite signicantly improved LVO recanalization rates. Around 35–40% of
AIS cases occur due to LVO, while 25–40% are caused by
medium-vessel occlusions (MeVOs). Characterized by distal
occlusion location and less ischemia, MeVO strokes have better
outcomes when compared with LVO strokes, but cohort studies
indicate that the outcomes are frequently poor, despite best medical management [82].
The exact denition of a medium-sized vessel also requires
consensus, as vessel size and anatomy may be subjected to
interobserver variability. MeVO was dened as an occlusion of
the M2/M3 middle cerebral artery/A2/A3 anterior cerebral artery
and P2/P3 posterior cerebral artery segments in a study with
pooled data from two multicenter prospective cohorts. In this
study, only 50.0% of patients with DMVO achieved an excellent
outcome (mRS score, 0–1) at 90 days, and 67.4% achieved an
independent outcome (mRS score, 0–2). Moreover, the authors
found that intravenous alteplase was signicantly associated with
lower mRS scores in mRS shift analysis, but no signicant association with excellent outcome (mRS score, 0–1) was noted.

ab
10 Endovascular Management and Treatment of Acute Ischemic…
221
Moreover, even in the alteplase group, early recanalization was
achieved in <50% of study cohort, suggesting insufcient efcacy
of intravenous alteplase as a stand-alone treatment for DMVO
strokes [83].
Data from a preliminary meta-analysis of 12 nonrandomized
studies indicated that EVT for patients with occlusions of M2 segment of middle cerebral artery that can be safely accessed is associated with high recanalization rates and good clinical outcomes
[84].
Until recently, endovascular treatment of DMVO was considered to have a high risk-benet ratio with less severe clinical decits and increased risk of iatrogenic complications. Additionally,
the isolated nature of decits associated with these and other
MeVOs (A2/A3/M3/P2/P3) such as abulia, quadrantanopia, aphasia, and ataxia makes NIHSS-based and protocolized patient
selection challenging (Fig. 10.4).
Determining the infarct core and penumbra accurately in
MeVO stroke may be challenging or not possible at all, as recent
literature suggests that we presently lack the ability to precisely
delineate infarct “core” with the commonly used imaging modali-
Fig. 10.4 Patient who presented with a distal right middle cerebral artery
occlusion. (a) Initial injection of the right internal carotid artery, parenchymal
phase, demonstrates an occlusion of a distal right middle cerebral artery
branch (M3/4) (yellow arrow) resulting in an area of lack of parenchymal
blood ow (blue arrow). (b) Patient underwent aspiration thrombectomy
resulting in recanalization of the occluded branch
Соседние файлы в папке Библиотека им академика М.И. Перельмана
